Simpson A J
Laboratory of Cancer Genetics, Ludwig Institute for Cancer Research, São Paulo, Brazil.
Adv Cancer Res. 1997;71:209-40. doi: 10.1016/s0065-230x(08)60100-1.
Much recent attention has been paid to the important role of the DNA mismatch repair system in controlling the accumulation of somatic mutations in human tissues and the association of mismatch repair deficiency with carcinogenesis. In the absence of an intact mismatch repair system, cells accumulate mutations at a rate some 1000 times faster than normal cells, and this mutator phenotype is easily measured by the detection of the formation of new variant alleles at microsatellite loci. However, the mismatch repair system is not 100% efficient, even when intact, and the pattern of microsatellite alterations in a wide variety of tumors is consistent with these being due to clonal amplification from tissues that are genetically heterogeneous at microsatellite loci rather than mismatch repair deficiency in the tumor itself. On this basis, it can be estimated that the mutation frequency of microsatellites in normal human tissues is approximately 10(-2) per locus per cell. Similarly, a frequency of mutation at minisatellite loci in normal tissues of around 10(-1) per locus per cell can be estimated. Such elevated levels of mutation are consistent with a recent study of the frequency of HPRT mutation in human kidneys that demonstrated these to be frequent (average 2.5 x 10(-4) in individuals of 70 years or more) and exponentially related to age. Taken as a whole, the data suggest that somatic mutation in human epithelial cells may be some 10-fold higher than in peripheral blood lymphocytes and that the underlying rate of spontaneous mutation is sufficient to account for a large proportion of human carcinogenesis without the need to evoke either stepwise alteration to a mutator phenotype of clonal expansion at all the mutation steps in carcinogenesis. The exponential increase in mutation frequency with age is predictable on the basis that the mutation rate is controlled at the level of repair and that mutation in genes that affect the efficiency of these processes will gradually increase the underlying rate. In addition, the age relatedness of mutation frequency strongly supports the concept that mutation is cell division dependent and that cellular proliferation per se is an important risk factor for cancer. Comparison of somatic mutations with those in the human germline mutation suggests common mechanistic origins and that the high levels of somatic mutation that occur are a direct reflection of the germline mutation rate selected over evolutionary time. Thus, the somatic accumulation of mutations can be seen as a natural process within the human body and cancer a normal part of the human life cycle. This point of view may explain why it has been so difficult to significantly reduce cancer incidence and suggests that, for this to be achieved, the means of altering the natural somatic mutation rate needs to be identified.
最近,DNA错配修复系统在控制人体组织中体细胞突变积累以及错配修复缺陷与致癌作用之间的关联方面所起的重要作用受到了广泛关注。在缺乏完整的错配修复系统的情况下,细胞积累突变的速度比正常细胞快约1000倍,并且这种突变体表型很容易通过检测微卫星位点上新的变异等位基因的形成来衡量。然而,错配修复系统即使完整也并非100%有效,并且多种肿瘤中微卫星改变的模式与这些改变是由于微卫星位点基因异质性组织的克隆扩增而非肿瘤本身的错配修复缺陷一致。基于此,可以估计正常人组织中微卫星的突变频率约为每个位点每个细胞10^(-2)。同样,可以估计正常组织中微小卫星位点的突变频率约为每个位点每个细胞10^(-1)。这种升高的突变水平与最近一项关于人肾中HPRT突变频率的研究一致,该研究表明这些突变很常见(70岁及以上个体中平均为2.5×10^(-4))且与年龄呈指数相关。总体而言,数据表明人类上皮细胞中的体细胞突变可能比外周血淋巴细胞高约10倍,并且潜在的自发突变率足以解释很大一部分人类致癌作用,而无需在致癌过程的所有突变步骤中引发向突变体表型的逐步改变或克隆扩增。基于突变率在修复水平上受到控制且影响这些过程效率的基因中的突变将逐渐增加潜在速率这一事实,突变频率随年龄呈指数增加是可预测的。此外,突变频率与年龄的相关性有力地支持了突变依赖于细胞分裂且细胞增殖本身是癌症重要风险因素的概念。体细胞突变与人类种系突变的比较表明存在共同的机制起源,并且发生的高水平体细胞突变是进化时间内选择的种系突变率的直接反映。因此,突变的体细胞积累可被视为人体内的一个自然过程,而癌症是人类生命周期的正常组成部分。这种观点可能解释了为何大幅降低癌症发病率如此困难,并表明要实现这一点,需要确定改变自然体细胞突变率的方法。